\
&
Contact us
\
&
Contact us
Published on | 2 years ago
Programmes Digital Europe HPC AI Continent Cybersecurity Advanced Digital Skills Deployment: Best use of technologies European Digital Innovation HubsThe European Commission has published the first calls under the 2023 Digital Europe work programme. The calls cover a broad range of topics under the special objectives AI, Data & Cloud, Advanced Digital Skills and Deployment: Accelerating Best Use of Technologies.
The calls will be open for submission of proposals as of 11 May 2023, the deadline is 26 September 2023.
We strongly advise the registered users of our website to check your profile (and if needed, update them) to ensure that you have not only selected to be informed on general aspects of the programme, but that you also selected the Special Objectives that are of interest to you.
Information on specific call topics (such as changes to the call texts, specific info sessions etc.) will be published on the dedicated pages of the Specific Objectives, not on the general Digital Europe page. Please make sure that you do not miss any relevant information.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
